Oramed Pharmaceuticals Inc. – NASDAQ:ORMP
Oramed Pharmaceuticals stock price today
$2.06
-0.31
-13.08%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 14 hours
Oramed Pharmaceuticals stock price monthly change
-5.95%
month
Oramed Pharmaceuticals stock price quarterly change
-5.95%
quarter
Oramed Pharmaceuticals stock price yearly change
+6.76%
year
Oramed Pharmaceuticals key metrics
Market Cap | 95.13M |
Enterprise value | 44.66M |
P/E | -2.35 |
EV/Sales | 16.52 |
EV/EBITDA | -1.36 |
Price/Sales | 31.16 |
Price/Book | 0.55 |
PEG ratio | 0.05 |
EPS | -0.37 |
Revenue | N/A |
EBITDA | -18.10M |
Income | -14.75M |
Revenue Q/Q | -100% |
Revenue Y/Y | -25.03% |
Profit margin | -1352.61% |
Oper. margin | -1501.96% |
Gross margin | 0% |
EBIT margin | -1501.96% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeOramed Pharmaceuticals stock price history
Oramed Pharmaceuticals stock forecast
Oramed Pharmaceuticals financial statements
| Dec 2022 | 681K | -8.54M | -1254.48% |
|---|---|---|---|
| Mar 2023 | 666K | -1.79M | -269.97% |
| Jun 2023 | 674K | -1.19M | -177.15% |
| Sep 2023 | 0 | -3.22M |
| Jun 2023 | 674K | -1.19M | -177.15% |
|---|---|---|---|
| Sep 2023 | 0 | -3.22M | |
| Sep 2025 | 1M | -3.64M | -364.01% |
| Dec 2025 | 1M | -4.44M | -444.9% |
Analysts Price target
Financials & Ratios estimates
| 2022-11-10 | -0.25 | -0.18 |
|---|---|---|
| 2023-03-06 | -0.21228 | -0.22 |
| Dec 2022 | 161642000 | 10.48M | 6.49% |
|---|---|---|---|
| Mar 2023 | 159780000 | 9.63M | 6.03% |
| Jun 2023 | 156314000 | 5.65M | 3.62% |
| Sep 2023 | 230893000 | 82.66M | 35.8% |
| Dec 2022 | -8.06M | 11.26M | 4.17M |
|---|---|---|---|
| Mar 2023 | -5.54M | -13.20M | 2.43M |
| Jun 2023 | -2.63M | -14.71M | 19.81M |
| Sep 2023 | -694K | -75.12M | 74.54M |
Oramed Pharmaceuticals alternative data
| Aug 2023 | 13 |
|---|---|
| Sep 2023 | 13 |
| Oct 2023 | 13 |
| Nov 2023 | 13 |
| Dec 2023 | 13 |
| Jan 2024 | 13 |
| Feb 2024 | 13 |
| Mar 2024 | 13 |
| Apr 2024 | 13 |
| May 2024 | 13 |
| Jun 2024 | 13 |
| Jul 2024 | 13 |
Oramed Pharmaceuticals other data
9.78%
-8.24%
of ORMP is owned by hedge funds
64
-22
3.79M
-2.89M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2023 | 0 | 13325 |
| Mar 2023 | 196000 | 100000 |
| Apr 2023 | 8809 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | MAYER ARIE director | Common Stock | 3,800 | $2.21 | $8,398 | ||
Purchase | MAYER ARIE director | Common Stock | 5,009 | $2.22 | $11,120 | ||
Purchase | KIDRON NADAV director, officer.. | Common Stock | 26,000 | $2.04 | $53,014 | ||
Purchase | KIDRON NADAV director, officer.. | Common Stock | 100,000 | $2.01 | $201,000 | ||
Sale | KIDRON MIRIAM director, officer.. | Common Stock | 100,000 | $2.01 | $201,000 | ||
Purchase | ROZOV YADIN director | Common Stock | 50,000 | $2.05 | $102,450 | ||
Purchase | ROZOV YADIN director | Common Stock | 20,000 | $1.96 | $39,120 | ||
Sale | RABINOWITZ MICHAEL officer: Chief Commercial Officer | Common Stock | 11,900 | $12.49 | $148,655 | ||
Sale | RABINOWITZ MICHAEL officer: Chief Commercial Officer | Common Stock | 1,425 | $13.01 | $18,544 | ||
Option | SANK LEONARD director | Stock Option | 20,000 | $4.08 | $81,600 |
-
What's the price of Oramed Pharmaceuticals stock today?
One share of Oramed Pharmaceuticals stock can currently be purchased for approximately $2.06.
-
When is Oramed Pharmaceuticals's next earnings date?
Unfortunately, Oramed Pharmaceuticals's (ORMP) next earnings date is currently unknown.
-
Does Oramed Pharmaceuticals pay dividends?
No, Oramed Pharmaceuticals does not pay dividends.
-
How much money does Oramed Pharmaceuticals make?
Oramed Pharmaceuticals has a market capitalization of 95.13M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 50.43% to 1.34M US dollars. Oramed Pharmaceuticals earned 5.53M US dollars in net income (profit) last year or -$0.22 on an earnings per share basis.
-
What is Oramed Pharmaceuticals's stock symbol?
Oramed Pharmaceuticals Inc. is traded on the NASDAQ under the ticker symbol "ORMP".
-
What is Oramed Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Oramed Pharmaceuticals?
Shares of Oramed Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Oramed Pharmaceuticals's key executives?
Oramed Pharmaceuticals's management team includes the following people:
- Mr. Nadav Kidron Esq. Pres, Chief Executive Officer & Executive Director(age: 51, pay: $1,150,000)
- Dr. Miriam Kidron Ph.D. Chief Scientific Officer & Director(age: 85, pay: $420,060)
- Mr. Michael Rabinowitz Chief Commercial Officer(age: 60, pay: $360,180)
- Mr. Joshua Hexter Chief Operating & Bus. Officer(age: 55, pay: $326,940)
- Mr. David Silberman Chief Financial Officer, Treasurer & Sec.(age: 42, pay: $182,530)
-
How many employees does Oramed Pharmaceuticals have?
As Jul 2024, Oramed Pharmaceuticals employs 13 workers.
-
When Oramed Pharmaceuticals went public?
Oramed Pharmaceuticals Inc. is publicly traded company for more then 18 years since IPO on 1 May 2007.
-
What is Oramed Pharmaceuticals's official website?
The official website for Oramed Pharmaceuticals is oramed.com.
-
Where are Oramed Pharmaceuticals's headquarters?
Oramed Pharmaceuticals is headquartered at 1185 Avenue of the Americas, New York, NY.
-
How can i contact Oramed Pharmaceuticals?
Oramed Pharmaceuticals's mailing address is 1185 Avenue of the Americas, New York, NY and company can be reached via phone at +84 49672633.
Oramed Pharmaceuticals company profile:
Oramed Pharmaceuticals Inc.
oramed.comExchange:
NASDAQ
Full time employees:
13
Industry:
Biotechnology
Sector:
Healthcare
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
1185 Avenue of the Americas
New York, NY 10036
New York, NY 10036
CIK: 0001176309
ISIN: US68403P2039
CUSIP: 68403P203
